Company: EDSA
Filing Date: 2025-08-08
Form Type: 10-Q
Source: 0001171843-25-005236
Chunk: 30

Company: Edesa Biotech, Inc.
Filing Date: 2025-08-08
Form: 10-Q
Item: Part I, Item 8
Chunk 30
---
 nine months ended June 30, 2025 compared to $3.2 million for the same period last year primarily due to a decrease in professional service fees and noncash share-based compensation. Our G&A expenses consist primarily of salaries and related costs for our employees in administrative, executive and finance functions. G&A expenses also include professional fees for legal, accounting, audit, tax and consulting services, insurance, office, and travel expenses.

Total other income decreased by $0.3 million to $0.5 million for the nine months ended June 30, 2025 compared to $0.8 million for the same period last year and was composed of the following:

			●

			Grant income remained decreased by $0.2 million to $0.5 million for the nine months ended June 30, 2025 compared to $0.6 million for the same period last year and the nine months ended June 30, 2024, respectively. The decrease is related to the grant income associated with the activities under the 2023 SIF Agreement.

			●

			Interest income decreased to $3,000 for the nine months ended June 30, 2025 compared to $137,000 for the same period last year primarily due to lower cash balances.

			●

			Foreign exchange loss was $54,000 for the nine months ended June 30, 2025 compared to a loss of $10,000 for the same period last year.

For the nine months ended June 30, 2025, our net loss was $5.0 million, or $0.95 per common share, compared to a net loss of $5.2 million, or $1.64 per common share for the nine months ended June 30, 2024.

Capital Expenditures

Our capital expenditures primarily consist of computer and office equipment. There were no significant capital expenditures for the three and nine months ended June 30, 2025 and 2024.

22

Liquidity and Capital Resources

As a clinical-stage company we have not generated significant revenue, and we expect to incur operating losses as we continue our efforts to acquire, develop, seek regulatory approval for and commercialize product candidates and execute on our strategic initiatives. Our operations have historically been funded through issuances of common shares, exercises of common share purchase warrants, convertible preferred shares, convertible loans, government grants and tax incentives.

Our primary use of cash is to fund our operating expenses,